NEXGEL Triples Revenue with Celularity Biomaterials Acquisition — NEXGEL, INC.

Event summary

NEXGEL acquires 6 commercial-stage regenerative biomaterial products from Celularity, tripling annual revenue to $35M.
Transaction expected to make NEXGEL immediately profitable upon closing.
Portfolio includes products for tendon repair, skin grafts, and bone growth with existing insurance reimbursement.
Three new 510(k) filings planned for 2026, 2027, and 2028.
Experienced commercial team from Celularity to join NEXGEL, expanding sales reach.

The big picture

This acquisition positions NEXGEL as a significant player in the regenerative biomaterials market, capitalizing on the growing demand for advanced medical technologies. The deal underscores a broader trend of consolidation in the biotech sector, where companies are seeking to scale through strategic acquisitions. The immediate profitability and revenue tripling highlight the strategic anomaly of NEXGEL’s rapid transformation from a niche hydrogel provider to a diversified medical technology company.

What we're watching

Revenue Integration: How NEXGEL will integrate the acquired products into its existing portfolio and maintain the projected revenue growth.
Regulatory Approvals: The pace at which the planned 510(k) filings will be approved and commercialized.
Team Synergy: Whether the incoming commercial team can effectively expand NEXGEL’s sales reach and operational capabilities.